With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1120-95-2,3-Chloropyridazine,as a common compound, the synthetic route is as follows.
Example 4-5 (Trans)-8-({[6-(3,5-dimethylphenyl)-3-pyridazinyl]amino}methyl)-3-(3-pyridazinyl)-1-oxa-3-azaspiro[4.5]decan-2-one dihydrochloride (Trans)-8-({[6-(3,5-dimethylphenyl)-3-pyridazinyl]amino}methyl)-1-oxa-3-azaspiro[4.5]decan-2-one (Intermediate 46, 20 mg, 0.055 mmol), trans-1,2-diaminocyclohexane (0.013 ml, 0.109 mmol), 3-chloropyridazine (prepared according to WO/0107416, 12.50 mg, 0.109 mmol), K3PO4 (34.8 mg, 0.164 mmol), copper(I) iodide (10.39 mg, 0.055 mmol) were suspended in 1,4-dioxane (4 ml) and shaken at 120 C. in a closed vial overnight. The resulting dark mixture was concentrated under vacuum, taken up with DCM (20 ml) and filtered over a separation tube. The organic solution was concentrated and purified with Biotage SP1 over a 12S NH2 Varian cartridge, eluding with a gradient of cyclohexane and EtOAc. (Trans)-8-({[6-(3,5-dimethylphenyl)-3-pyridazinyl]amino}methyl)-3-(3-pyridazinyl)-1-oxa-3-azaspiro[4.5]decan-2-one was eluted with ca 70% EtOAc and recovered as a colourless oil (12 mg, 0.027 mmol, 49%). 1H NMR (400 MHz, CDCl3): delta 8.97 (dd, 1H), 8.58 (dd, 1H), 7.63-7.61 (m, 3H), 7.50 (dd, 1H), 7.07 (br s, 1H), 6.73 (d, 1H), 4.86 (br t, 1H), 4.23 (s, 2H), 3.46 (t, 2H), 2.41 (s, 6H), 2.12-1.07 (m, 9H); HPLC-MS: 1.69 min, 445 [M+H]+., 1120-95-2
As the paragraph descriping shows that 1120-95-2 is playing an increasingly important role.
Reference£º
Patent; Biagetti, Matteo; Contini, Stefania Anna; Genski, Thorsten; Guery, Sebastien; Leslie, Colin Philip; Mazzali, Angelica; Pizzi, Domenica Antonia; Sabbatini, Fabio Maria; Seri, Catia; US2009/203705; (2009); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem